Plain-English translation of NCT05365659 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This clinical trial is testing a new medication called for people with advanced B-cell non-Hodgkin lymphomas that have not responded well to previous treatments. The study has two parts: first, researchers will test different doses of the medication to find the safest and most effective dose, and then they will give that dose to larger groups of patients with specific types of lymphoma to learn more about how well it works.
Many people with advanced B-cell lymphomas run out of effective treatment options after trying standard therapies. This medication is being studied because early research suggests it may help patients whose cancer has come back or stopped responding to other drugs.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion (through a vein in your arm) on the first day of each 21-day cycle. In the first part of the study, different patients receive different doses to find the safest level; in the second part, all patients receive the dose that was determined to be best. You can continue treatment as long as the medication is helping and you are not experiencing unacceptable side effects, and you will have regular check-ups and blood tests to monitor your progress and safety.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States
Australia